The impact of the metabolic syndrome on cardiovascular risk and disease in rheumatoid arthritis

Future Rheumatology

Volumn 3, Issue 4, 2008, Pages 335-349

  Dessein, Patrick H ^a,b   Gonzalez Gay, Miguel A ^c   Woodiwiss, Angela J ^a   Joffe, Barry I ^a   Norton, Gavin R ^a   Solomon, Ahmed ^d  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b MILPARK HOSPITAL   (South Africa)

^c HOSPITAL XERAL CALDE   (Spain)

^d UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

Cardiometabolic risk; Cardiovascular disease; Glucocorticoids; High grade inflammation; Hypothyroidism; Insulin resistance; Metabolic syndrome; Obesity; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GLUCOCORTICOID; INFLIXIMAB; METHOTREXATE; PREDNISONE;

ATHEROGENESIS; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DISEASE ACTIVITY; DRUG MEGADOSE; DYSLIPIDEMIA; GOUT; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; METABOLIC SYNDROME X; OBESITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS;

EID: 55649084106     PISSN: 17460816     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460816.3.4.335     Document Type: Review

References (95)

1. Gabriel SE, Crowson CS, O'Fallen WM: Comorbidity in arthritis. J. Rheumatol. 26(11), 2475-2479 (1994).
2. Del Rincon ID, Williams K, Stern MP, Freeman GL, Escalante A: High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum. 44(12), 2737-2745 (2001).
3. Solomon DH, Karlson EW, Rimm EB et al.: Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 107(9), 1030-1307 (2003).
4. Wolfe F, Freundlich B, Straus WL: Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis. J. Rheumatol. 30(1), 36-40 (2003).
5. Watson D, Rhodes T, Guess H: All-cause mortality and vascular events among patients with RA, OA, or no arthritis in the UK General Practice Research Database. J. Rheumatol. 30(6), 1196-1202 (2003).
6. Fischer LM, Schlienger RG, Matter C, Jick H, Meler CR: Effect of rheumatoid arthritis or systemic lupus erythematosus on the risk of first-time acute myocardial infarction. Am. J. Cardiol. 93(2), 198-200 (2004).
7. Maradit-Kremers H, Crowson CS, Nicola PJ et al.: Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis. Arthritis Rheum. 52(2), 402-411 (2005).
8. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Final report. Circulation 106(3), 3143-3342 (2002).
9. Grundy SM, Pasternak R, Greenland P, Smith S, Fuster V: Assessment of cardiovascular risk by use of multiple-risk-factor assessment equation. Circulation 100(13), 1481-1492 (1999).
10. Conroy RM, Pyorala K, Fitzgerald AP et al.: Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur. Heart J. 24(11), 987-1003 (2003).
11. Grundy SM, Brewer B Jr, Cleeman JI, Smith SC Jr, Lenfant C: Definition of metabolic syndrome. Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on scientific issues related to definition. Circulation 109(3), 433-438 (2004).
12. Grundy SM, Cleeman JI, Daniels SR et al.: Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blond Institute scientific statement. Circulation 112(15), 2735-2752 (2005).
13. Grundy SM: Controversy in clinical endocrinology. Metabolic syndrome: a multiplex cardiovascular risk factor. J. Clin. Endocrinol. Metab. 92(2). 399-404 (2007).
14. Eckel RH, Grundy SM, Zimmet PZ: The metabolic syndrome. Lancet 365 (9468) 1415-1428 (2005).
15. Ford ES, Giles WH, Dietz WH: Prevalence of the metabolic syndrome among US adults. Findings from the Third National Health and Nutrition Examination Survey. J. Am. Med. Assoc. 287(3) 356-359 (2002).
16. Hotamisligil GS, Shargill NS, Spiegelman BM: Adipose expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance. Science 259(5091), 87-91 (1993).
17. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM: IRS-1 mediated inhibition of insulin receptor tyrosine kinase activity in TNF-α- and obesity-induced insulin resistance. Science 271(5249), 665-668 (1996).
18. Rui L, Yuan M, Frantz D, Shoelson S, White MF: SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2. J. Biol. Chem. 277(44), 42394-42398 (2002).
19. Ridker PM, Wilson PW, Grundy SM: Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation 109(23), 2818-2825 (2004).
20. Sattar N, McCarey DW, Capell H, McInnes IB: Explaining how 'high-grade' systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 108(25), 2957-2963 (2003).
21. Dessein PH, Joffe BI, Stanwix AE: Inflammation, insulin resistance, and aberrant lipid metabolism as cardiovascular risk factors in rheumatoid arthritis. J. Rheumatol. 30(7), 1403-1405 (2003).
22. Gonzalez-Gay MA, Gonzalez-Juanatey C, Martin J: Rheumatoid arthritis: a disease associated with accelerated atherogenesis. Semin. Arthritis Rheum. 35(1), 8-17 (2005).
23. Kylin E: [Hypertension-hyperglycemia-hyperuricemia syndrome]. Zentralblatt fur innere Medizin 44 (1923).
24. Vague J: [Sexual differentiation as a determinant of forms of obesity]. Presse Med. 3, 339-340 (1947)
25. Reaven GM: Role of insulin resistance in human disease. Diabetes 37(12), 1595-1607 (1988).
26. Kahn R, Buse J, Ferrannini E, Stern M: The metabolic syndrome: time for a critical appraisal. Joint statement from the American diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 28(9), 2289-2304 (2005).
27. Alberti KG, Zimmet P, Shaw J: The metabolic syndrome - a new worldwide definition. Lancet 366(9491), 1059-1062 (2005).
28. Grundy SM: Does a diagnosis of metabolic syndrome have value in clinical practice? Am. J. Clin. Nutr. 83(6), 1248-1251 (2006).
29. Gami AS, Witt BJ, Howard DE et al.: Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J. Am. Coll. Cardiol. 49(4), 403-414 (2007).
30. Ross R: Atherosclerosis - an inflammatory disease. N. Engl. J. Med. 340(2), 115-126 (1999).
31. Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R: Metabolic syndrome. A comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 111(11), 1448-1454 (2005).
32. Grundy SM: Obesity, metabolic syndrome, and cardiovascular disease. J. Clin. Endocrinol. Metab. 89(6), 2595-2600 (2004).
33. Reaven G: The metabolic syndrome: requiescat in pace. Clin. Chem. 51(6), 931-938 (2005).
34. Festa A, D'Agostino R Jr, Howard G, Mykkanen L, Tracy RP, Haffner SM: Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 102(1), 42-47 (2000).
35. Reilly MP, Wolfe ML, Rhodes T, Girman C, Mehta N, Rader DJ: Measures of insulin resistance add incremental value to the clinical diagnosis of metabolic syndrome in association with coronary atherosclerosis. Circulation 110(7), 803-809 (2004).
36. Saely CH, Aczel S, Marte T, Langer P, Hoefle G, Drexel H: The metabolic syndrome, insulin resistance, and cardiovascular risk in diabetic and nondiabetic patients. J. Clin. Endocrinol. Metab. 90(10), 5698-5703 (2005).
37. Iribarren C, Go AS, Husson G et al.: Metabolic syndrome and early-onset coronary artery disease. Is the whole greater than its parts? J. Am. Coll. Cardiol. 48(9), 1800-1807 (2006).
38. Sattar N, McConnachie A, Shaper AG et al.: Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies. Lancet 371(9628), 1927-1935 (2008).
39. Dessein PH, Joffe BI, Veller MG et al.: Traditional and nontraditional cardiovascular risk factors are associated with atherosclerosis in rheumatoid arthritis. J. Rheumatol. 32(3), 435-442 (2005).
40. del Rincon I, Freeman GL, Haas RW, O'Leary DH, Escalante A: Relative contribution of cardiovascular risk factors and rheumatoid arthritis clinical manifestations to atherosclerosis. Arthritis Rheum. 52(11), 3413-3423 (2005).
41. Dessein PH, Norton GR, Woodiwiss AJ, Joffe BI, Wolfe F: Influence of nonclassical cardiovascular risk factors on the accuracy of predicting subclinical atherosclerosis in rheumatoid arthritis. J. Rheumatol. 34(5), 943-951 (2007).
42. Gonzalez-Gay MA, Gonzalez-Juanatey C, Lopez-Diaz MJ et al.: HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis. Arthritis Rheum. 57(1), 125-132 (2007).
43. Dessein PH, Joffe BI, Singh S: Biomarkers of endothelial dysfunction, cardiovascular risk factors and atherosclerosis in rheumatoid arthritis. Arthritis Res. Ther. 7(3), R634-R643 (2003).
44. Chung CP, Oeser A, Solus JF et al.: Prevalence of the metabolic syndrome is increased in rheumatoid arthritis and is associated with coronary atherosclerosis. Atherosclerosis 196(2), 756-763 (2008).
45. Stavropoulos-Kalinoglou A, Metsios GS, Koutedakis Y et al.: Redefining overweight and obesity in rheumatoid arthritis. Ann. Rheum. Dis. 66(10), 1316-1321 (2007).
46. Rall LC, Roubenoff R: Rheumatoid cachexia: metabolic abnormalities, mechanisms and intervention. Rheumatology 43(10), 1219-1223 (2004).
47. Dessein PH, Joffe BI: Insulin resistance and impaired β cell function in rheumatoid arthritis. Arthritis Rheum. 54(9), 2765-2775 (2006).
48. Westhoff G, Rau R, Zink A: Radiographic joint damage in early rheumatoid arthritis is highly dependent on body mass index. Arthritis Rheum. 56(11), 3575-3582 (2007).
49. van der Helm-van Mil AH, van der Kooij SM, Allaart CF, Toes RE. Hulzinga TW: A high body mass index is protective on the amount of joint destruction in small joints in early rheumatoid arthritis. Ann. Rheum. Dis. 67(6), 769-774 (2008).
50. Garcia-Poma A, Segami MI, More CS et al.: Obesity is independently associated with impaired quality of life in patients with rheumatoid arthritis. Clin. Rheumatol. 26(11), 1831-1835 (2007).
51. Leirisalo Repo M, Mottonen T, Hannonen P et al.: Increasing body mass index is associated with reduced rate of remission in early rheumatoid arthritis. Arthritis Rheum. 56(9 Suppl.), S820 (2007)
52. Grundy SM: Atherogenic dyslipidemia associated with metabolic syndrome and insulin resistance. Clin. Cornerstone 8(Suppl. 1), S21-S27 (2006).
53. Hu FB, Willett WC, Li T et al.: Adiposity as compared with physical activity in predicting mortality among women. N. Engl. J. Med. 351(26), 2694-2703 (2004).
54. Adams KF, Schatzkin A, Harris TB et al.: Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. N. Engl. J. Med. 355(8), 763-768 (2006).
55. Kremers HM, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE: Prognostic importance of low body mass index in relation to cardiovascular mortality in rheumatoid arthritis. Arthritis Rheum. 50(11), 3450-3457 (2004).
56. Escalante A, Haas RW, de Rincon I: Paradoxical effect of body mass index on survival in rheumatoid arthritis. Arch. Intern. Med. 165(14), 1624-1629 (2005).
57. Svenson KL, Lundqvist G, Wide L, Hallgren R: Impaired glucose handling in active rheumatoid arthritis: relationship to the secretion of insulin and counter-regulatory hormones. Metabolism 36(10), 941-943 (1987).
58. Svenson KL, Pollare T, Lithell H, Hallgren R: Impaired glucose handling in active rheumatoid arthritis: relationship to peripheral insulin resistance. Metabolism 37(2), 125-130 (1988).
59. Paolisso G, Valentini G, Giugliano D et al.: Evidence for peripheral impaired glucose handling in patients with connective tissue diseases. Metabolism 40(9), 902-907 (1991).
60. Dessein PH, Joffe BI, Stanwix A, Botha AS, Moomal Z: The acute phase response does not fully predict the presence of insulin resistance and dyslipidemia in inflammatory arthritis. J. Rheumatol. 29(3), 462-466 (2002).
61. Dessein PH, Stanwix AE, Joffe BI: Cardiovascular risk in rheumatoid arthritis versus osteoarthritis: acute phase response related decreased insulin sensitivity and high-density lipoprotein cholesterol as well as clustering of metabolic syndrome features in rheumatoid arthritis. Arthritis Res. 4, R5 (2002).
62. Dessein PH, Joffe BI, Stanwix A: Effects of disease modifying agents and dietary intervention on insulin resistance and dyslipidemia in inflammatory arthritis: a pilot study. Arthritis Res. 4, R12 (2002).
63. Gonzalez-Gay MA, De Matias JM, Gonzalez-Juanatey C et al.: Anti-tumor necrosis factor-α blockade improves insulin resistance in patients with rheumatoid arthritis. Clin. Exp. Rheumatol. 24(1), 83-86 (2006).
64. Kiortsis DN, Mavridis AK, Vasakos TD et al.: Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis. Ann. Rheum. Dis. 64(5), 765-766 (2005).
65. Tam LS, Tomlinson B, Chu TT et al.: Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis. Clin. Rheumatol. 26(9), 1495-1498 (2007).
66. Rosenvinge A, Krogh-Madsen R, Baslund B, Pedersen BK: Insulin resistance in patients with rheumatoid arthritis: effect of anti-TNF α therapy. Scand. J. Rheumatol. 36(2), 91-96 (2007).
67. Wolfe F, Michaud K: Corticosteroids increase the risk of diabetes mellitus in rheumatoid arthritis and contribute to the risk of myocardial infarction and heart failure. Ann. Rheum. Dis. 63(Suppl. 1), 495 (2004).
68. Dessein PH, Joffe BI, Stanwix AE, Christian BF, Veller M: Glucocorticoids and insulin sensitivity in rheumatoid arthritis. J. Rheumatol. 31(5), 867-874 (2004).
69. Boers M, Nurmohamed MT, Doelman CJ et al.: Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis. Ann. Rheum. Dis. 62(9), 842-845 (2003).
70. Panoulas VF, Douglas KM, Stavropoulos-Kalinoglou A et al.: Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis. Rheumatology 47(1), 72-75 (2008).
71. Dessein PH, Joffe BI, Stanwix AE: Subclinical hypothyroidism is associated with insulin resistance in rheumatoid arthritis. Thyroid 14(6), 443-446 (2004).
72. Dessein PH, Norton GR, Woodiwiss AJ, Joffe BI, Solomon A: Independent role of conventional cardiovascular risk factors as predictors of C-reactive protein concentrations in rheumatoid arthritis. J. Rheumatol. 34(4), 681-688 (2007).
73. Pedersen LM, Nordin H, Svensson B, Bliddal H: Microalbuminuria in patients with rheumatoid arthritis. Ann. Rheum. Dis. 54(3), 189-192 (1995).
74. McEntegart A, Capell HA, Creran D, Rumley A, Woodward M, Lowe GDO: Cardiovascular risk factors, including thrombotic variables, in a population with rheumatoid arthritis. Rheumatology 40(6), 640-644 (2001).
75. Straub RH, Harle P, Sarzi-Puttini P, Cutolo M: Tumor necrosis factor-neutralizing therapies improve altered hormone axes. Arthritis Rheum. 54(7), 2039-2046 (2006).
76. Panoulas VF, Milionis HJ, Douglas KMJ et al.: Association of serum uric acid with cardiovascular disease in rheumatoid arthritis. Rheumatology 46(9), 1466-1470 (2007).
77. Panoulas VF, Douglas KM, Milionis HJ et al.: Serum uric acid is independently associated with hypertension in patients with rheumatoid arthritis. J. Hum. Hypertens. 22(3), 177-182 (2008).
78. Feig DI, Mazzali M, Kang DK et al.: Serum uric acid: a risk factor and a target for treatment? J. Am. Soc. Nephrol. 17(4), S69-S73 (2006).
79. Boers M, Breedveld FC, Kijkmans BAC et al.: Raised plasma renin and prorenin in rheumatoid vasculitis. Ann. Rheum. Dis. 49(7), 517-520 (1990).
80. Dessein PH, Woodiwiss AJ, Joffe BI, Norton GR: Aminotransferases are associated with insulin resistance and atherosclerosis in rheumatoid arthritis. BMC Cardiovasc. Disord. 7, 31 (2007).
81. Ehling A, Schaffler A, Herfarth H et al.: The potential of adiponectin in driving arthritis. J. Immunol. 176(7), 4468-4478 (2006).
82. Gonzalez-Gay MA, Llorca J, Garcia-Unzueta MT et al.: High-grade inflammation, circulating adiponectin concentrations and cardiovascular risk factors in severe rheumatoid arthritis. Clin. Exp. Rheumatol. (In press).
83. Nagashima T, Okubo-Fornbacher H, Aoki Y et al.: Increase in plasma levels of adiponectin after administration of anti-tumor necrosis factor agents in patients with rheumatoid arthritis. J. Rheumatol. 35(5), 1936-1938 (2008).
84. Harle P, Sarzi-Puttini P, Cutolo M, Straub RH: No change of serum levels of leptin and adiponectin during anti-tumour necrosis factor antibody treatment with adalimumab in patients with rheumatoid arthritis. Ann. Rheum. Dis. 65(7), 1970-1971 (2006).
85. Senolt L, Pavelka K, Housa D, Haluzik M: Increased adiponectin is negatively linked to the local inflammatory process in patients with rheumatoid arthritis. Cytokine 35(5-6), 247-252 (2006).
86. Dessein PH, Tobias M, Veller MG: Metabolic syndrome and subclinical atherosclerosis in rheumatoid arthritis. J. Rheumatol. 33(12), 2425-2432 (2006).
87. Dessein PH, Joffe BI: When is a patient with rheumatoid arthritis at risk for cardiovascular disease? J. Rheumatol. 33(2), 201-203 (2006).
88. Gonzalez-Gay MA, Gonzalez-Juanatey C, Pineiro A, Garcia-Porrua C, Testa A, Llorca J: High-grade C-reactive protein elevation correlates with accelerated atherogenesis in patients with rheumatoid arthritis. J. Rheumatol. 32(7), 1219-1223 (2005).
89. del Rincon I, O'Leary DH, Haas RW, Escalante A: Effect of glucocorticoids on the arteries in rheumatoid arthritis. Arthritis Rheum. 50(12), 3813-3822 (2004).
90. Raterman HG, van Halm VP, Voskuyl AE, Simsek S, Dijkmans BAC, Nurmohamed MT: Rheumatoid arthritis is associated with a high prevalence of hypothyroidism that amplifies its cardiovascular risk. Ann. Rheum. Dis. 67(2), 229-232 (2008).
91. Wallberg-Jonsson S, Cederfelt M, Rantapaa Dahlqvist S: Hemostatic factors and cardiovascular disease in active rheumatoid arthritis: an 8 year followup study. J. Rheumatol. 27(1), 71-75 (2000).
92. Dessein PH, Joffe BI, Stanwix AE: Should we evaluate insulin sensitivity in rheumatoid arthritis? Semin. Arthritis Rheum. 35(1), 5-7 (2005).
93. Pamuk ON, Unlu E, Cakir N: Role of insulin resistance in increased frequency of atherosclerosis detected by carotid ultrasonography in rheumatoid arthritis. J. Rheumatol. 33(12), 2447-2452 (2006).
94. La Montagna G, Cacciapuoti F, Buono R et al.: Insulin resistance is an idependent risk factor for atherosclerosis in rheumatoid arthritis. Diabetes Vasc. Dis. Res. 4(2), 130-135 (2007).
95. Karvounaris SA, Sidiropoulos PI, Papadakis JA et al.: Metabolic syndrome is common among middle-to-older aged Mediterranean patients with rheumatoid arthritis and correlates with disease activity: a retrospective, cross-sectional, controlled, study. Ann. Rheum. Dis. 66(1), 28-33 (2007).